Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)
Status:
Completed
Trial end date:
2008-02-14
Target enrollment:
Participant gender:
Summary
This is a dose-ranging study that will evaluate the efficacy, safety and tolerability of a
range of doses of investigational product and pioglitazone, compared to placebo, administered
as monotherapy over 12 weeks in treatment naive patients with T2DM